Search Result

Results for "

AXL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TAM Receptor (61) ADC Antibody (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (10) Autophagy (1) c-Fms (2) c-Kit (6) c-Met/HGFR (20) Discoidin Domain Receptor (4) E1/E2/E3 Enzyme (1) FGFR (1) FLT3 (16) HIF/HIF Prolyl-Hydroxylase (2) IGF-1R (2) Isotope-Labeled Compounds (1) JAK (1) PDGFR (1) PROTACs (2) RIP kinase (1) ROS Kinase (2) Small Interfering RNA (siRNA) (1) Trk Receptor (4) VEGFR (11) VSV (1) YAP (3)
By Research Areas:	Cancer (77) Cardiovascular Disease (2) Endocrinology (2) Infection (2) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (1)

By Targets:

TAM Receptor (61)

ADC Antibody (2)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (10)

Autophagy (1)

c-Fms (2)

c-Kit (6)

c-Met/HGFR (20)

Discoidin Domain Receptor (4)

E1/E2/E3 Enzyme (1)

FGFR (1)

FLT3 (16)

HIF/HIF Prolyl-Hydroxylase (2)

IGF-1R (2)

Isotope-Labeled Compounds (1)

JAK (1)

PDGFR (1)

PROTACs (2)

RIP kinase (1)

ROS Kinase (2)

Small Interfering RNA (siRNA) (1)

Trk Receptor (4)

VEGFR (11)

VSV (1)

YAP (3)

By Research Areas:

Cancer (77)

Cardiovascular Disease (2)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (8)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: TAM Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-144706

Axl-IN-3

TAM Receptor Cancer

Axl-IN-3 is a potent, selective and orally active AXL kinase inhibitor with an IC₅₀ of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases .
HY-144708

Axl-IN-4

TAM Receptor Cancer

Axl-IN-4 (Compound 24) is an AXL kinase inhibitor with an IC₅₀ of 28.8 μM .

Axl-IN-3	TAM Receptor	Cancer
Axl-IN-3 is a potent, selective and orally active AXL kinase inhibitor with an IC₅₀ of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases .

Axl-IN-4	TAM Receptor	Cancer
Axl-IN-4 (Compound 24) is an AXL kinase inhibitor with an IC₅₀ of 28.8 μM .

HY-162103

Axl-IN-18	TAM Receptor Apoptosis	Cancer
Axl-IN-18 (compound 25c) is a potent and selective type II *AXL* inhibitor. Axl-IN-18 shows excellent AXL inhibitory activity (IC₅₀=1.1 nM) and 343-fold selectivity over the highly homologous kinase MET in biochemical assays (IC₅₀=377 nM). Axl-IN-18 significantly inhibits AXL-driven cell proliferation, dose-dependently suppresses 4T1 cell migration and invasion, and induces apoptosis. Axl-IN-18 shows noticeable antitumor efficacy in a BaF3/TEL-AXL xenograft model .

HY-153277

Axl/Mer/CSF1R-IN-2

TAM Receptor c-Fms Neurological Disease

Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and CSF1R inhibitor .
HY-162085

Axl-IN-17

TAM Receptor Cancer

Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC₅₀ value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .

Axl/Mer/CSF1R-IN-2	TAM Receptor c-Fms	Neurological Disease
Axl/Mer/CSF1R-IN-2 (Comp 4) is a *Axl, Mer* and CSF1R inhibitor .

Axl-IN-17	TAM Receptor	Cancer
Axl-IN-17 (compound 13c) is an orally active, selective *AXL* inhibitor with an IC₅₀ value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .

HY-N12041

Axl-IN-16	TAM Receptor HIF/HIF Prolyl-Hydroxylase	Cancer
Axl-IN-16 is a dual inhibitor of *Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl*-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-152075

AXL-IN-14	TAM Receptor	Cancer
AXL-IN-14 is a potent and orally active *AXL* inhibitor with an IC₅₀ value of 0.8 nM. AXL-IN-14 inhibits Gas6/AXL-mediated cell migration and invasion. AXL-IN-14 decreases the expression of p-AXL and p-AKT proteins. AXL-IN-14 shows anti-tumor activity .

HY-146596

Axl-IN-5

TAM Receptor Cancer

Axl-IN-5 (compound 1) is a AXL inhibitor with an IC₅₀ of 283 nM. Axl-IN-5 has anticancer effects .
HY-153441

AXL-IN-15

TAM Receptor Cancer

AXL-IN-15 (cpd391) is a potent Axl inhibitor with both K_i and IC₅₀ <1 nM. AXL-IN-15 can be used for research in cancer .

Axl-IN-5	TAM Receptor	Cancer
Axl-IN-5 (compound 1) is a *AXL* inhibitor with an IC₅₀ of 283 nM. Axl-IN-5 has anticancer effects .

AXL-IN-15	TAM Receptor	Cancer
AXL-IN-15 (cpd391) is a potent *Axl* inhibitor with both K_i and IC₅₀ <1 nM. AXL-IN-15 can be used for research in cancer .

HY-147577

Axl-IN-10	TAM Receptor	Inflammation/Immunology Cancer
Axl-IN-10 (Example 1) is a potent *AXL* inhibitor, with an IC₅₀ of 5 nM. Axl-IN-10 has excellent transmembrane properties.Axl-IN-10 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-10 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .

HY-147576

Axl-IN-9	TAM Receptor	Inflammation/Immunology Cancer
Axl-IN-9 (Example 10) is a potent *AXL* inhibitor, with an IC₅₀ of 26 nM. Axl-IN-9 has excellent transmembrane properties. Axl-IN-9 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-9 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .

HY-147574

Axl-IN-7	TAM Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Axl-IN-7 (Chemie 22) is a potent *AXL* inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease .

HY-147575

Axl-IN-8	TAM Receptor c-Met/HGFR	Cancer
Axl-IN-8 (NO.1) is a potent *AXL* inhibitor, with an IC₅₀ of <1 nM. Axl-IN-8 also inhibits c-MET, with an IC₅₀ of 1-10 nM. Axl-IN-8 shows anti-proliferative activity against BaF3/TEL-AXL, MKN45, and EBC-1 cells, with IC₅₀ values of <10, 226.6 and 120.3 nM, respectively .

HY-146615

Axl-IN-6	TAM Receptor	Cancer
Axl-IN-6 (compound 14) is an orally active and potent *AXL* inhibitor. Axl-IN-6 is well tolerated and significantly inhibits the tumor growth in MV-4-11 subcutaneous xenograft model .

HY-147578

Axl-IN-11	TAM Receptor	Infection Inflammation/Immunology Cancer
Axl-IN-11 (Example 1) is a potent *AXL* inhibitor. Axl-IN-11 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .

HY-147579

Axl-IN-12	TAM Receptor	Infection Inflammation/Immunology Cancer
Axl-IN-12 (Example 2) is a potent *AXL* inhibitor. Axl-IN-12 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .

HY-151904

AXL-IN-13	TAM Receptor FLT3 PDGFR	Cancer
AXL-IN-13 is a potent and orally active *AXL* inhibitor (IC₅₀: 1.6 nM, K_d: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion .

HY-153012

Axl/Mer/CSF1R-IN-1

TAM Receptor c-Fms Cancer

Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with K_ds of <0.1 μM .

Axl/Mer/CSF1R-IN-1	TAM Receptor c-Fms	Cancer
Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with K_ds of <0.1 μM .

HY-RS01293

AXL Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
AXL Human Pre-designed siRNA Set A contains three designed siRNAs for AXL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AXL Human Pre-designed siRNA Set A AXL Human Pre-designed siRNA Set A

HY-15494

Picropodophyllin 15+ Cited Publications AXL1717; Picropodophyllotoxin; PPP	IGF-1R Apoptosis	Endocrinology Cancer
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-15494S1

Picropodophyllin-d6 AXL1717-d₆; Picropodophyllotoxin-d₆; PPP-d₆	Isotope-Labeled Compounds IGF-1R Apoptosis	Endocrinology Cancer
Picropodophyllin-d₆ (AXL1717-d₆) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-P1790

Axltide

JAK Metabolic Disease

Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

Axltide	JAK	Metabolic Disease
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

HY-144627

*PROTAC Axl* Degrader 2**	PROTACs TAM Receptor	Cancer
PROTAC Axl Degrader 2 is a potent and selective PROTAC Axl degrader with an IC₅₀ of 1.61 µM. PROTAC Axl Degrader 2 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 2 induces mehuosis .

HY-144624

*PROTAC Axl* Degrader 1**	PROTACs TAM Receptor	Cancer
PROTAC Axl Degrader 1 is a potent and selective PROTAC Axl degrader with an IC₅₀ of 0.92 µM. PROTAC Axl Degrader 1 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 1 induces mehuosis .

HY-149491

HIV-IN-7	TAM Receptor HIF/HIF Prolyl-Hydroxylase	Others
Axl-IN-16 (Compound 4) is a *Axl* inhibitor. Axl-IN-16 inhibits *Axl* expression and inhibits the activity of HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 can be isolated from“fruiting liquid (FL)” of Hypholoma lateritium and Hericium erinaceus .

HY-P99360

Enapotamab Anti-AXL/UFO Reference Antibody (enapotamab)	TAM Receptor	Cancer
Enapotamab is an *anti-AXL/UFO* reference antibody. Enapotamab can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates .

HY-124502

UNC4203	TAM Receptor FLT3	Cancer
UNC4203 is a potent, orally available and highly selective MERTK inhibitor, with IC₅₀s of 1.2 nM, 140 nM, 42 nM and 90 nM for MERTK, AXL, TYRO3 and FLT3, respectively .

HY-P99734

Mipasetamab uzoptirine ADCT-601	TAM Receptor	Cancer
Mipasetamab uzoptirine (ADCT-601) is an *AXL*-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers .

HY-155310

AF-2112

YAP Cancer

AF-2112 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2.

AF-2112	YAP	Cancer
AF-2112 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2.

HY-155309

LM-41	YAP	Cancer
LM-41 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 inhibits migration of human MDA-MB-231 breast cancer cells .

HY-138696

Zanzalintinib 1 Publications Verification XL092	TAM Receptor c-Met/HGFR VEGFR	Cancer
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, *AXL* and MER, with IC₅₀s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research .

HY-114358

Tamnorzatinib ONO-7475	TAM Receptor Trk Receptor	Cancer
Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).

HY-117596

UNC569 1 Publications Verification	TAM Receptor	Cancer
UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC₅₀ of 2.9 nM and a K_i of 4.3 nM. UNC569 also inhibits *Axl* and Tyro3 with IC₅₀s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research

HY-114357A

DS-1205b free base	TAM Receptor c-Met/HGFR Trk Receptor	Cancer
DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC₅₀ of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC₅₀s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo .

HY-12494

LDC1267 5+ Cited Publications	TAM Receptor	Inflammation/Immunology Cancer
LDC1267 is a highly selective *TAM (Tyro3, Axl* and Mer) kinase inhibitor with IC₅₀*s of <5 nM/8 nM/29 nM for Tyro3,Axl* and Mer respectively .

HY-P99161

Tilvestamab BGB149	TAM Receptor	Cancer
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks *AXL*-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced *AXL* activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in *AXL* overexpressing renal cell carcinomas .

HY-12432A

Gilteritinib hemifumarate 20+ Cited Publications ASP2215 hemifumarate	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive *FLT3/AXL* inhibitor with IC₅₀ of 0.29 nM/0.73 nM, respectively.

HY-12432

Gilteritinib 20+ Cited Publications ASP2215	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) is a potent and ATP-competitive *FLT3/AXL* inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

HY-12432S1

Gilteritinib-d8 ASP2215-d₈	FLT3 TAM Receptor	Cancer
Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-149092

Anticancer agent 109	TAM Receptor	Cancer
Anticancer agent 109 (compound 6-15) is an inhibitor of the *Gas6-Axl* axis with anti-cancer activity. Anticancer agent 109 inhibits the expression of Gas6 and Axl, and the expression p-PI3K and p-AKT in cancer cells, leads to G1 phase arrest and promotes cancer cells apoptosis, and inhibits tumor growth significantly in nude mouse tumor bearing models .

HY-150041

TL4830031	TAM Receptor	Cancer
TL4830031 (compound 8i), a quinolone antibiotic derivatives, is a potent *Axl* inhibitor with an IC₅₀ value of 26 nM. TL4830031 inhibits the phosphorylation of Axl. TL4830031 inhibits cell invasion and migration. TL4830031 can be used for cancer research .

HY-15150

Bemcentinib

35+ Cited Publications

R428; BGB324
TAM Receptor Cancer

Bemcentinib (R428) is a potent and selective inhibitor of Axl with an IC₅₀ of 14 nM .

Bemcentinib 35+ Cited Publications R428; BGB324	TAM Receptor	Cancer
Bemcentinib (R428) is a potent and selective inhibitor of *Axl* with an IC₅₀ of 14 nM .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to *AXL, a tyrosine kinase receptor* and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .

HY-16961

Sitravatinib 1 Publications Verification MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-16961A

Sitravatinib malate MGCD516 malate; MG-516 malate	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-162406

UNC8969	Others	Cancer
UNC8969 (compound 43) is a *MERTK/AXL* dual inhibitor with IC₅₀s of 1.1±0.8 nM for MERTK and 5.3 ± 2.7 nM for AXL. UNC8969 also exerts a T_1/2 of 7.3 h with 5 mg/kg i.v. in mice .

HY-P9988

Mecbotamab BA301	ADC Antibody TAM Receptor	Cancer
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)
TAM Receptor Cancer

Bemcentinib (R428) GMP is an orally active and selective inhibitor of Axl with an IC₅₀ of 14 nM .

HY-12963

Dubermatinib 5+ Cited Publications TP-0903	TAM Receptor Apoptosis	Cancer
Dubermatinib (TP-0903) is a potent and selective *Axl* receptor tyrosine kinase inhibitor with an IC₅₀ value of 27 nM.

HY-100509

NPS-1034

1 Publications Verification

TAM Receptor c-Met/HGFR Apoptosis Cancer

NPS-1034 is a dual inhibitor of AXL and MET with IC₅₀s of 10.3 and 48 nM, respectively.

Cat. No.	Product Name	Target	Research Area

HY-P99360

Enapotamab Anti-AXL/UFO Reference Antibody (enapotamab)	TAM Receptor	Cancer
Enapotamab is an *anti-AXL/UFO* reference antibody. Enapotamab can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates .

HY-P99161

Tilvestamab BGB149	TAM Receptor	Cancer
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks *AXL*-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced *AXL* activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in *AXL* overexpressing renal cell carcinomas .

HY-P99734

Mipasetamab uzoptirine ADCT-601	TAM Receptor	Cancer
Mipasetamab uzoptirine (ADCT-601) is an *AXL*-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to *AXL, a tyrosine kinase receptor* and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .

HY-P9988

Mecbotamab BA301	ADC Antibody TAM Receptor	Cancer
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .

HY-P99463

Batiraxcept AVB-S6-500	TAM Receptor	Cancer
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with *AXL, thereby substantially reducing AXL* signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15494

Picropodophyllin 15+ Cited Publications AXL1717; Picropodophyllotoxin; PPP	Structural Classification Classification of Application Fields Source classification Lignans Dysosma versipellis (Hance) M. Cheng ex Ying Phenylpropanoids Plants Berberidaceae Disease Research Fields Endocrinology	IGF-1R Apoptosis
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-N12041

Axl-IN-16	Structural Classification Natural Products Microorganisms Source classification	TAM Receptor HIF/HIF Prolyl-Hydroxylase
Axl-IN-16 is a dual inhibitor of *Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl*-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-N3634

Corylifol C	Structural Classification Leguminosae Source classification Phenols Polyphenols Psoralea corylifolia L. Plants	Others
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

Species:	Human (10) Mouse (2) Cynomolgus (1)
Tag:	His (9) Avi (3) GST (1) Fc (4)
Source:	HEK293 (12) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P74406

	AXL Protein, Mouse (HEK293, His-Fc) Tyrosine-protein kinase receptor UFO; AXL oncogene; UFO	Mouse	HEK293
	The AXL protein has predicted roles in various cellular functions, binds to phosphatidylinositol 3-kinase and phosphatidylserine, and serves as a viral receptor. It negatively regulates apoptosis and positively regulates protein kinase B signaling. AXL Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived AXL protein, expressed by HEK293 , with C-hFc, C-His labeled tag. The total length of AXL Protein, Mouse (HEK293, His-Fc) is 424 a.a., with molecular weight of 95-120 kDa.

HY-P74407

	AXL Protein, Human (449a.a, HEK293, His) Tyrosine-protein kinase receptor UFO; AXL oncogene; UFO	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (449a.a, HEK293, His) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-His labeled tag. The total length of AXL Protein, Human (449a.a, HEK293, His) is 417 a.a., with molecular weight of 55-90 kDa.

HY-P702703

	AXL Protein, Human (Biotinylated, sf9, GST, Avi) AXL; AXL receptor tyrosine kinase; tyrosine-protein kinase receptor UFO; JTK11; UFO; AXL oncogene; oncogene AXL; AXL transforming sequence/gene	Human	Sf9 insect cells

HY-P700587

	AXL Protein, Human (HEK293, C-His) AXL receptor tyrosine kinase; tyrosine-protein kinase receptor UFO; JTK11; UFO; AXL oncogene; oncogene AXL; AXL transforming sequence/gene	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (HEK293, C-His) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-10*His labeled tag. The total length of AXL Protein, Human (HEK293, C-His) is 426 a.a., with molecular weight of 48.9 kDa.

HY-P700585

	AXL Protein, Human (D266N, HEK293, His) AXL receptor tyrosine kinase; tyrosine-protein kinase receptor UFO; JTK11; UFO; AXL oncogene; oncogene AXL; AXL transforming sequence/gene	Human	HEK293
	AXL Protein, a receptor tyrosine kinase, mediates signals by binding GAS6, regulating cell survival, proliferation, migration, and differentiation. Upon ligand binding, AXL undergoes dimerization and autophosphorylation, activating downstream molecules like PI3-kinase subunits, GRB2, PLCG1, and more. This triggers AKT kinase activation, influencing processes such as endothelial cell survival, cytokine signaling in NK cell development, hepatic regeneration, gonadotropin-releasing hormone neuron function, platelet activation, thrombotic responses, and immune modulation. AXL also serves as a receptor for lassa virus and lymphocytic choriomeningitis virus during microbial infection. AXL Protein, Human (D266N, HEK293, His) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-10*His labeled tag and D266N mutation. The total length of AXL Protein, Human (D266N, HEK293, His) is 426 a.a., with molecular weight of 48.9 kDa.

HY-P700586

	AXL Protein, Human (D266N, HEK293, hFc) AXL receptor tyrosine kinase; tyrosine-protein kinase receptor UFO; JTK11; UFO; AXL oncogene; oncogene AXL; AXL transforming sequence/gene	Human	HEK293
	AXL Protein, a receptor tyrosine kinase, mediates signals by binding GAS6, regulating cell survival, proliferation, migration, and differentiation. Upon ligand binding, AXL undergoes dimerization and autophosphorylation, activating downstream molecules like PI3-kinase subunits, GRB2, PLCG1, and more. This triggers AKT kinase activation, influencing processes such as endothelial cell survival, cytokine signaling in NK cell development, hepatic regeneration, gonadotropin-releasing hormone neuron function, platelet activation, thrombotic responses, and immune modulation. AXL also serves as a receptor for lassa virus and lymphocytic choriomeningitis virus during microbial infection. AXL Protein, Human (D266N, HEK293, hFc) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-hFc labeled tag and D266N mutation. The total length of AXL Protein, Human (D266N, HEK293, hFc) is 426 a.a., with molecular weight of 75.1 kDa.

HY-P77875

	AXL Protein, Human (HEK293, Fc) AXL; UFO; AXL oncogene; AXL; ARK; JTK11; Tyro7; AI323647; EC 2.7.10; EC 2.7.10.1	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (HEK293, Fc) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-hFc labeled tag. The total length of AXL Protein, Human (HEK293, Fc) is 424 a.a., with molecular weight of 80-110 kDa.

HY-P77876

	AXL Protein, Human (Biotinylated, HEK293, Fc) AXL; UFO; AXL oncogene; AXL; ARK; JTK11; Tyro7; AI323647; EC 2.7.10; EC 2.7.10.1	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (Biotinylated, HEK293, Fc) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-hFc labeled tag. The total length of AXL Protein, Human (Biotinylated, HEK293, Fc) is 424 a.a., with molecular weight of 80-110 kDa.

HY-P77877

	AXL Protein, Human (HEK293, His-Avi) AXL; UFO; AXL oncogene; AXL; ARK; JTK11; Tyro7; AI323647; EC 2.7.10; EC 2.7.10.1	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (HEK293, His-Avi) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of AXL Protein, Human (HEK293, His-Avi) is 424 a.a., with molecular weight of 70-80 kDa.

HY-P77878

	AXL Protein, Human (Biotinylated, HEK293, His-Avi) AXL; UFO; AXL oncogene; AXL; ARK; JTK11; Tyro7; AI323647; EC 2.7.10; EC 2.7.10.1	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of AXL Protein, Human (Biotinylated, HEK293, His-Avi) is 424 a.a., with molecular weight of 70-80 kDa.

HY-P77567

	AXL Protein, Cynomolgus (417a.a, HEK293, His) AXL; UFO; AXL oncogene; AXL; ARK; JTK11; Tyro7; AI323647; EC 2.7.10; EC 2.7.10.1	Cynomolgus	HEK293
	AXL Protein, a receptor tyrosine kinase, mediates signals by binding GAS6, regulating cell survival, proliferation, migration, and differentiation. Upon ligand binding, AXL undergoes dimerization and autophosphorylation, activating downstream molecules like PI3-kinase subunits, GRB2, PLCG1, and more. This triggers AKT kinase activation, influencing processes such as endothelial cell survival, cytokine signaling in NK cell development, hepatic regeneration, gonadotropin-releasing hormone neuron function, platelet activation, thrombotic responses, and immune modulation. AXL also serves as a receptor for lassa virus and lymphocytic choriomeningitis virus during microbial infection. AXL Protein, Cynomolgus (417a.a, HEK293, His) is the recombinant cynomolgus-derived AXL protein, expressed by HEK293 , with C-His labeled tag. The total length of AXL Protein, Cynomolgus (417a.a, HEK293, His) is 417 a.a., with molecular weight of 68-70 kDa.

HY-P7623

	AXL Protein, Mouse (HEK293, His) rMuAXL, His; Tyrosine-protein kinase receptor UFO; AXL oncogene; UFO	Mouse	HEK293
	AXL Protein, Mouse (HEK293, His), a recombinant mouse AXL produced in HEK293 cells, has a His tag. AXL is a member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 (GAS6). Anti-cancer activity.

HY-P7622

	AXL Protein, Human (415a.a, HEK293, His) 1 Publications Verification rHuAXL, His; Tyrosine-protein kinase receptor UFO; AXL oncogene; UFO	Human	HEK293
	AXL Protein, Human (HEK293, His), a recombinant human AXL produced in HEK293 cells, has a His tag. AXL is a member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 (GAS6). Anti-cancer activity.

Cat. No.	Product Name	Chemical Structure

HY-12432S1

Gilteritinib-d8

Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].